We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) generated positive results from an interim analysis of the phase III DUO-O study, which evaluated a combination of its blockbuster cancer drugs Lynparza (olaparib) and Imfinzi (durvalumab) in certain patients with advanced ovarian cancer.
The DUO-O study is evaluating the safety and efficacy of the combination of Imfinzi, Lynparza, chemotherapy and bevacizumab (“Lynparza plus Imfinzi arm”) against chemotherapy plus bevacizumab (“control arm”) in newly-diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations.
The interim analysis of data from the DUO-O study showed that the Lynparza plus Imfinzi arm achieved a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (“PFS”) over the control arm. The safety profile of the combinations was also consistent with the profile of individual medications.
Since the data from the study is still immature, AstraZeneca is currently unable to assess key secondary endpoints (like overall survival) of the study. The company expects to provide an update on the same after further data analysis.
In the year so far, shares of AstraZeneca have gained 3.6% against the industry’s 2.0% fall.
Image Source: Zacks Investment Research
Management also announced that an additional arm of the study evaluating the combination of Imfinzi, chemotherapy and bevacizumab did not achieve statistical significance for PFS in the interim analysis against the control arm.
Imfinzi is already approved for multiple cancer indications. While the drug is already approved for two NSCLC indications, it is also approved in extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer (BTC) and hepatocellular carcinoma (uHCC) indications.
AstraZeneca markets Lynparza in partnership with Merck (MRK - Free Report) . AstraZeneca/Merck’s Lynparza is approved for four cancer types, namely ovarian, breast, prostate and pancreatic. In 2022, Lynparza generated product sales of $2.6 billion for AstraZeneca and alliance revenues of $1.1 billion for Merck.
The profit-sharing deal between AstraZeneca and Merck was inked in 2017. In addition to Lynparza, the deal included Koselugo.
AstraZeneca is focused on strengthening its oncology business. In 2022, AZN generated $14.6 billion worth of total revenues from its Oncology business, reflecting a 19% year-over-year rise in the constant exchange rate, driven by a solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. Management is working to further strengthen this portfolio through label expansions and advancing oncology pipeline candidates. AstraZeneca aims to develop a treatment for every form of cancer.
In the past 60 days, estimates for Certara’s 2023 earnings per share have increased from 46 cents to $1.24. During the same period, the earnings estimates per share for 2024 have risen from 54 cents to $1.85. Shares of Certara are up 43.8% in the year-to-date period.
Earnings of Certara missed estimates in two of the last four quarters, beating the mark on one occasion while meeting the mark on another. On average, the company’s earnings witnessed a negative surprise of 3.25%. In the last reported quarter, Certara’searnings beat estimates by 14.29%.
In the past 60 days, estimates for CRISPR Therapeutics’ 2023 loss per share have narrowed from $8.21 to $7.35. Shares of CRISPR Therapeutics have risen 7.5% in the year-to-date period.
Earnings of CRISPR Therapeutics beat estimates in two of the last four quarters while missing the mark on the other two occasions, witnessing an earnings surprise of 3.19%, on average. In the last reported quarter, CRISPR Therapeutics’ earnings beat estimates by 39.22%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
AstraZeneca (AZN - Free Report) generated positive results from an interim analysis of the phase III DUO-O study, which evaluated a combination of its blockbuster cancer drugs Lynparza (olaparib) and Imfinzi (durvalumab) in certain patients with advanced ovarian cancer.
The DUO-O study is evaluating the safety and efficacy of the combination of Imfinzi, Lynparza, chemotherapy and bevacizumab (“Lynparza plus Imfinzi arm”) against chemotherapy plus bevacizumab (“control arm”) in newly-diagnosed patients with advanced high-grade epithelial ovarian cancer without tumor BRCA mutations.
The interim analysis of data from the DUO-O study showed that the Lynparza plus Imfinzi arm achieved a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (“PFS”) over the control arm. The safety profile of the combinations was also consistent with the profile of individual medications.
Since the data from the study is still immature, AstraZeneca is currently unable to assess key secondary endpoints (like overall survival) of the study. The company expects to provide an update on the same after further data analysis.
In the year so far, shares of AstraZeneca have gained 3.6% against the industry’s 2.0% fall.
Image Source: Zacks Investment Research
Management also announced that an additional arm of the study evaluating the combination of Imfinzi, chemotherapy and bevacizumab did not achieve statistical significance for PFS in the interim analysis against the control arm.
Imfinzi is already approved for multiple cancer indications. While the drug is already approved for two NSCLC indications, it is also approved in extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer (BTC) and hepatocellular carcinoma (uHCC) indications.
AstraZeneca markets Lynparza in partnership with Merck (MRK - Free Report) . AstraZeneca/Merck’s Lynparza is approved for four cancer types, namely ovarian, breast, prostate and pancreatic. In 2022, Lynparza generated product sales of $2.6 billion for AstraZeneca and alliance revenues of $1.1 billion for Merck.
The profit-sharing deal between AstraZeneca and Merck was inked in 2017. In addition to Lynparza, the deal included Koselugo.
AstraZeneca is focused on strengthening its oncology business. In 2022, AZN generated $14.6 billion worth of total revenues from its Oncology business, reflecting a 19% year-over-year rise in the constant exchange rate, driven by a solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. Management is working to further strengthen this portfolio through label expansions and advancing oncology pipeline candidates. AstraZeneca aims to develop a treatment for every form of cancer.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the overall healthcare sector Certara (CERT - Free Report) and CRISPR Therapeutics (CRSP - Free Report) . While Certara sports a Zacks Rank #1 (Strong Buy), CRISPR Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Certara’s 2023 earnings per share have increased from 46 cents to $1.24. During the same period, the earnings estimates per share for 2024 have risen from 54 cents to $1.85. Shares of Certara are up 43.8% in the year-to-date period.
Earnings of Certara missed estimates in two of the last four quarters, beating the mark on one occasion while meeting the mark on another. On average, the company’s earnings witnessed a negative surprise of 3.25%. In the last reported quarter, Certara’searnings beat estimates by 14.29%.
In the past 60 days, estimates for CRISPR Therapeutics’ 2023 loss per share have narrowed from $8.21 to $7.35. Shares of CRISPR Therapeutics have risen 7.5% in the year-to-date period.
Earnings of CRISPR Therapeutics beat estimates in two of the last four quarters while missing the mark on the other two occasions, witnessing an earnings surprise of 3.19%, on average. In the last reported quarter, CRISPR Therapeutics’ earnings beat estimates by 39.22%.